Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health Inc (NQ: GH )

24.81 -0.06 (-0.24%)
Streaming Delayed Price Updated: 11:17 AM EDT, Sep 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Guardant Health Inc

< Previous 1 2 3 4 5 6 Next >
Guardant Health Reports Second Quarter 2021 Financial Results
From Guardant Health, Inc.
Via Business Wire
Fight Colorectal Cancer and Guardant Health Join Forces to Recognize Excellence in Overcoming Challenges to Colorectal Cancer Screening During Pandemic
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Second Quarter Financial Results on August 5, 2021
From Guardant Health, Inc.
Via Business Wire
Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling
From Guardant Health, Inc.
Via Business Wire
CORRECTING and REPLACING Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity
From Guardant Health
Via Business Wire
CORRECTING and REPLACING Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer
From Guardant Health, Inc.
Via Business Wire
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen’s LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health Files Lawsuit Against Natera for Misleading Oncologists
From Guardant Health, Inc.
Via Business Wire
Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT™ (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in Upcoming June Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers
From Guardant Health, Inc.
Via Business Wire
Guardant Health Reports First Quarter 2021 Financial Results
From Guardant Health, Inc.
Via Business Wire
Guardant Health Appoints Craig Eagle, MD as Chief Medical Officer
From Guardant Health, Inc.
Via Business Wire
Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity
From Guardant Health
Via Business Wire
Guardant Health to Participate in the BofA Securities 2021 Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Collaboration With Daiichi Sankyo to Develop Guardant360® CDx as a Companion Diagnostic for Enhertu® in Advanced Metastatic Non-Small Cell Lung Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report First Quarter Financial Results on May 6, 2021
From Guardant Health, Inc.
Via Business Wire
Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of Advanced Cancers
From Guardant Health, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.